Fasting Mimicking Diet May Be Safe, Effective as Adjunct to Chemo for Breast Cancer
The findings indicated that a fasting mimicking diet is safe and effective as an adjunct to chemotherapy in women with early breast cancer.
Related Articles
Post-Surgery Treatment of Localized Kidney Cancer
Sumanta Kumar Pal, MD, FASCO, joins Rohit Gosain, MD, and Rahul Gosain, MD, to discuss risk stratification and treatment practices for patients with localized kidney…
Increased Thyroid Cancer Risk Not Observed After Use of GLP1 Receptor Agonist
Patients who are predisposed to medullary thyroid cancer should be advised against the use of GLP1 agents.
Sacituzumab Tirumotecan Shows Early Efficacy in Gastric/GEJ Cancers
Sacituzumab tirumotecan elicited responses prominently in the second- and third-line and beyond setting and in those with high TROP2 expression.
FDA Approves Alectinib for Early-Stage ALK+ NSCLC
The FDA has approved alectinib for the adjuvant treatment of patients with ALK-positive non-small cell lung cancer with tumors that are least 4 cm or…
Younger Patients With HER2+ Breast Cancer May Benefit from Surgery First
Those aged 18 to 40 years with invasive, HER2-positive breast cancer showed a survival benefit from upfront surgery over neoadjuvant chemotherapy.
PET Imaging Agent Earns FDA Fast Track Designation in Recurrent Glioma
TLX101 is currently under assessment as a treatment for glioma in the IPAX-2 and IPAX-Linz studies.
FDA Approves Pegulicianine-Based Imaging for Breast Cancer Surgery
Results from the INSITE trial support the utility of pegulicianine fluorescence-guided surgery during breast cancer surgery.
Survival Outcomes Improve With TIL Presence in TNBC
An increased TIL count in the breast tissue was associated with improved distant recurrence-free survival in patients with triple-negative breast cancer.
Durvalumab Combo Yields OS Benefit in Advanced Biliary Tract Cancer
The phase 3 TOPAZ-1 trial of durvalumab plus chemotherapy showed a significant benefit vs chemotherapy alone for patients with advanced biliary tract cancer.
Response Observed With Savolitinib Combo in EGFR, MET, Osimertinib-Resistant NSCLC
A proteogenomic analysis found savolitinib plus osimertinib elicited a response in patients with EGFR-mutated, MET-amplified advanced NSCLC.